Aqilion receives SEK 100 million through conversion of outstanding warrants
In March of 2018, AQILION AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of “units.” Each unit consisted of one (1) share and two (2) warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which raised an additional SEK 100 million for the company. The issue was carried out to fund the restructuring of Aqilion’s strategy and organization, as well as the development of current and new pharmaceutical projects in the pipeline. “It is